Vertex Pharmaceuticals Incorporated engages in the discovery, development, manufacture, and commercialization of small molecule drugs for patients with serious diseases in specialty markets. The Company markets KALYDECO in the United States and international markets for the treatment of patients six years of age and older with cystic fibrosis (CF), who have a specific genetic mutation in their CF transmembrane conductance regulator (CFTR), gene, which is referred to as the G551D mutation. INCIVEK is approved in the United States and Canada for the treatment of adults with genotype 1 hepatitis C virus, or HCV, infection. The Company’s business is focused on developing and commercializing therapies for the treatment of CF and advancing its other research and early-stage development programs.

Official website: